Abeona Therapeutics Inc (ABEO) Shares Bought by Parkside Advisors LLC
Parkside Advisors LLC raised its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 16.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 14,530 shares of the biopharmaceutical company’s stock after acquiring an additional 2,000 shares during the period. Parkside Advisors LLC’s holdings in Abeona Therapeutics were worth $104,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc lifted its position in Abeona Therapeutics by 7.6% in the third quarter. Vanguard Group Inc now owns 1,539,008 shares of the biopharmaceutical company’s stock worth $19,699,000 after buying an additional 108,333 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Abeona Therapeutics during the third quarter worth $3,823,000. Vanguard Group Inc. lifted its position in shares of Abeona Therapeutics by 7.6% during the third quarter. Vanguard Group Inc. now owns 1,539,008 shares of the biopharmaceutical company’s stock worth $19,699,000 after purchasing an additional 108,333 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Abeona Therapeutics by 75.6% during the third quarter. Teachers Advisors LLC now owns 98,192 shares of the biopharmaceutical company’s stock worth $1,257,000 after purchasing an additional 42,261 shares during the last quarter. Finally, Nexthera Capital LP lifted its position in shares of Abeona Therapeutics by 35.6% during the third quarter. Nexthera Capital LP now owns 849,979 shares of the biopharmaceutical company’s stock worth $10,880,000 after purchasing an additional 223,175 shares during the last quarter. Institutional investors and hedge funds own 72.30% of the company’s stock.
Shares of Abeona Therapeutics stock traded down $0.09 during trading on Friday, hitting $7.14. 258,240 shares of the stock traded hands, compared to its average volume of 417,725. The firm has a market cap of $350.47 million, a P/E ratio of -10.82 and a beta of 1.84. Abeona Therapeutics Inc has a 52-week low of $6.26 and a 52-week high of $22.00.
Several analysts have recently weighed in on the company. Citigroup decreased their target price on Abeona Therapeutics from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, November 13th. Cantor Fitzgerald set a $36.00 target price on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 1st. Mizuho reiterated a “buy” rating and set a $17.00 target price on shares of Abeona Therapeutics in a research report on Monday, December 10th. BidaskClub downgraded Abeona Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 22nd. Finally, ValuEngine downgraded Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 11th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. Abeona Therapeutics presently has a consensus rating of “Buy” and an average price target of $26.78.
COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/abeona-therapeutics-inc-abeo-shares-bought-by-parkside-advisors-llc/2740598.html.
Abeona Therapeutics Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Read More: Growth Stocks
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.